Skip to main content
Professor Peptides
Research compound

CJC-1295 + GHRP-2 Blend

Also known as CJC-1295 + GHRP-2 · CJC/GHRP-2 blend

GHRH plus a more potent, less selective GHRP than ipamorelin

Last reviewed · Educational reference — not medical advice.

Half-life
Not characterised in published human pharmacokinetic studies
Route
Subcutaneous injection in reported research use
Status
Compounded blend — no controlled studies of the combination located
Mechanism
GHRH analogue plus ghrelin receptor agonist, as with the ipamorelin blend, but with GHRP-2 providing greater GH-releasing potency alongside additional cortisol and prolactin stimulation.
01

Overview

This blend follows the same dual-pathway logic as CJC-1295 with ipamorelin — a GHRH analogue on the stimulatory arm, a ghrelin receptor agonist acting through a separate receptor and reducing somatostatin tone — but substitutes GHRP-2 for ipamorelin.

That substitution is a real trade, not a preference. GHRP-2 is generally regarded as more potent at driving GH release than ipamorelin, but it is less selective: GHRP-2 also stimulates cortisol and prolactin release, which ipamorelin was specifically designed to avoid. Choosing this blend over the ipamorelin version means accepting additional endocrine effects in exchange for greater GH output.

Whether that trade is worthwhile has not been studied in the blend form. As with all compounded blends here, no controlled trial of the combination was located, and the DAC/no-DAC ambiguity in 'CJC-1295' applies equally.

See our individual CJC-1295 and GHRP-2 entries.

Research areasGrowth hormone axis regulationGHRP receptor pharmacologyCortisol and prolactin regulation
02

What the evidence shows

Separated by study type
HumanClinical trials and human studies
No controlled trial of this specific compounded combination was located.
AnimalRodent and other animal models
No controlled studies of the specific blend located.
In vitroCell and tissue studies
Receptor pharmacology of each component is separately characterised.
03

Key studies & findings

1 study
  1. 1

    No controlled trial of this compounded combination was located. The distinguishing feature versus the ipamorelin blend is GHRP-2's greater potency alongside its additional cortisol and prolactin stimulation.

    No combination trial located

04

Benefits & effects

2 documented

  • Greater GH-releasing potency than the ipamorelin equivalent

    Verified

  • Dual-pathway GH axis stimulation

    Verified
05

Side effects & safety

2 reported

Safety noteCompounded blend of research compounds for laboratory use only. Premixed blends compound the unknowns of each component and add one of their own: if an adverse effect occurs, the responsible component cannot be identified.

Recorded in the cited literature No safety data for the combination.

  • Cortisol elevation from GHRP-2

    Moderateunknown

  • Prolactin elevation from GHRP-2

    Moderateunknown
06

Limitations & open questions

This is a fixed-ratio premixed combination, and that carries specific consequences beyond those of its individual components. The components cannot be titrated independently — adjusting one means adjusting all of them. If a reaction occurs, attribution is impossible. And the combination itself has not been studied: evidence for the individual compounds does not transfer to the mixture, because combined pharmacology is not the sum of separate pharmacologies. Blends are a convenience and pricing format, not a validated pharmacological unit. GHRP-2's cortisol and prolactin stimulation is the specific cost of choosing it over ipamorelin, and in a fixed-ratio blend that cost cannot be dialled back independently. The CJC-1295 DAC/no-DAC ambiguity applies here as well.

07

Pharmacology

A mixture rather than a single chemical entity. Pharmacokinetics depend on which CJC-1295 form is present. See the individual entries for component chemistry.

08

Frequently asked questions

How does this differ from the CJC-1295 + ipamorelin blend?

GHRP-2 replaces ipamorelin. GHRP-2 is generally more potent at releasing GH but less selective — it also raises cortisol and prolactin, which ipamorelin was designed to avoid.

Is more GH release simply better?

Not necessarily. The additional cortisol and prolactin stimulation are real endocrine effects, and in a fixed-ratio blend you cannot reduce them without reducing everything else too.